possible role of soluble fibrin monomer complex after gastroenterological surgery

Table 3 The relationship between the soluble fibrin monomer complex on POD 1 and the clinical characteristics of the patients

Clinical risk factors for VTE	SFMC (POD 1)		Univariate	Multivariate
	Low(< 3.8)	High(≥ 3.8)	P value	OR	95%CI	P value
Age
< 75	59	27	0.01	2.44	1.07-5.66	0.03
≥ 75	16	21
Sex
Male	45	23	0.18
Female	30	25
BMI (kg/m2)
< 27	71	47	0.37
≥ 27	4	1
Performance status
0-2	73	46	0.64
3-4	2	2
Operative time (min)
< 321	45	18	0.01	2.33	1.08-5.12	0.02
≥ 321	30	30
Bleeding volume (mL)
< 113	47	28	0.63
≥ 113	28	20
Laparoscopic surgery
No	25	12	0.32
Yes	50	36
Malignancy
Absence	5	0	0.06
Presence	70	48
Metastatic disease
Absence	65	42	0.89
Presence	10	6
Diabetes mellitus
Absence	67	40	0.33
Presence	8	8
Varicose vein
Absence	75	47	0.2
Presence	0	1
Hormone therapy
Absence	72	47	0.55
Presence	3	1
CV catheter
Absence	72	47	0.55
Presence	3	1
Preoperative infection
Absence	71	45	0.83
Presence	4	3
Cardiovascular disease
Absence	73	44	0.15
Presence	2	4
Antiplatelet therapy
Absence	72	41	0.03	3.04	0.74-15.30	0.12
Presence	3	7
Pelvic surgery
Absence	62	39	0.84
Presence	13	9
Caprini score
< 7	36	17	0.16
≥ 7	39	31
Fibrin-related markers
D-dimer (μg/mL) < 0.6	26	11	0.12
Preoperative ≥ 0.6	30	25

SFMC: Soluble fibrin monomer complex; POD: Postoperative day; VTE: Venous thromboembolism; BMI: Body mass index; CV: Central vein.